Effects of new generation triptans - frovatriptan and almotriptan - on hemodynamic parameters in intact male and female rats

The introduction of the second generation triptans in clinical and experimental practice was a major progress in the pharmacotherapy of migraine. Frovatriptan is a second generation triptan with strong 5-HT1B/1D serotonergic agonism and low 5-HT1A/7 receptor affinity, while almotriptan possesses not...

Full description

Saved in:
Bibliographic Details
Published in:Acta Pharmaceutica 2020-06, Vol.70 (2), p.239-247
Main Authors: Saracheva, Kremena, Hrischev, Petar, Vasileva, Liliya, Topolov, Mariyan, Nikolova, Julia, Getova, Damianka
Format: Article
Language:English
Subjects:
Affinity
almotriptan
Animal behavior
Animals
arterial pressure
Blood pressure
Carbazoles - pharmacology
Drug therapy
Female
frovatriptan
Headache
Heart rate
Hemodynamics
Hemodynamics - drug effects
Male
Migraine
rat
Rats
Rats, Wistar
Receptor, Serotonin, 5-HT1F
Receptors, Serotonin - metabolism
Rodents
Serotonin Receptor Agonists - pharmacology
Serotonin S1 receptors
Tryptamines - pharmacology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The introduction of the second generation triptans in clinical and experimental practice was a major progress in the pharmacotherapy of migraine. Frovatriptan is a second generation triptan with strong 5-HT1B/1D serotonergic agonism and low 5-HT1A/7 receptor affinity, while almotriptan possesses not only the typical 5-HT1B/1D receptor agonist activity, but shows an affinity to the 5-HT1F receptor. The aim of our study was to assess the impact of frovatriptan and almotriptan on hemodynamics in male and female rats. We used a non-invasive "tail-cuff" method to measure the arterial blood pressure. Female and male Wistar rats were treated separately with high and low dosages of frovatriptan and almotriptan. Male and female rats showed reduction in all hemodynamic parameters, but only male rats showed an increase in the heart rate. In general, we could say that both almotriptan and frovatriptan potentiate cardiovascular safety.
ISSN:1846-9558
1330-0075
1846-9558
DOI:10.2478/acph-2020-0005